Suppr超能文献

局部晚期鼻咽癌的最佳诱导化疗方案:一项更新的贝叶斯网络Meta分析

Optimal induction chemotherapy regimen for locoregionally advanced nasopharyngeal carcinoma: an update Bayesian network meta-analysis.

作者信息

Wu Qiuji, Li Shaojie, Liu Jia, Zhong Yahua

机构信息

Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.

出版信息

Eur Arch Otorhinolaryngol. 2022 Nov;279(11):5057-5069. doi: 10.1007/s00405-022-07435-2. Epub 2022 Jun 29.

Abstract

BACKGROUND AND PURPOSE

Induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT) has been established as standard of care for locoregionally advanced nasopharyngeal carcinoma (LANPC). No direct comparison between different IC regimens has been performed. We conducted Bayesian network meta-analysis to evaluate the efficacy and safety of IC regimens in LANPC.

MATERIALS AND METHODS

We systematically searched studies comparing different regimens of IC plus CCRT versus CCRT alone for LANPC. Pairwise meta-analysis and Bayesian network meta-analysis were conducted using Review Manger, Stata and R software.

RESULTS

Eight eligible studies with a total of 2382 patients were involved. Compared with CCRT alone, IC + CCRT significantly improved PFS (HR = 0.68 [95% CI 0.59-0.79]) and OS (HR = 0.72 [95% CI 0.61-0.86]) in conventional meta-analysis. In Bayesian network meta-analysis, GP (gemcitabine and cisplatin) had advantage in prolonging PFS, OS and DMFS. GP had adverse but manageable impacts on hemoglobin and platelet. Meanwhile, treatment compliance of GP was higher than that of other regimens.

CONCLUSION

Based on existing evidences, GP could likely to be recommended as an optimal IC regimen for LANPC.

摘要

背景与目的

诱导化疗(IC)联合同步放化疗(CCRT)已被确立为局部晚期鼻咽癌(LANPC)的标准治疗方案。尚未对不同的IC方案进行直接比较。我们进行了贝叶斯网络荟萃分析,以评估IC方案在LANPC中的疗效和安全性。

材料与方法

我们系统检索了比较不同IC联合CCRT方案与单纯CCRT方案治疗LANPC的研究。使用Review Manger、Stata和R软件进行成对荟萃分析和贝叶斯网络荟萃分析。

结果

共纳入8项符合条件的研究,总计2382例患者。在传统荟萃分析中,与单纯CCRT相比,IC + CCRT显著改善了无进展生存期(HR = 0.68 [95% CI 0.59 - 0.79])和总生存期(HR = 0.72 [95% CI 0.61 - 0.86])。在贝叶斯网络荟萃分析中,GP(吉西他滨和顺铂)在延长无进展生存期、总生存期和远处转移无进展生存期方面具有优势。GP对血红蛋白和血小板有不良但可控的影响。同时,GP的治疗依从性高于其他方案。

结论

基于现有证据,GP可能被推荐为LANPC的最佳IC方案。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验